Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Immunology

Internal Medicine

Pediatrics

Infectious Diseases

Show all topics

DOI

10.1016/s1470-2045(21)00213-8

License

CC-BY

Other Formats

PDF